SCHEMBL9110970

SCHEMBL9110970

COC(=O)c1ccc(C2=CC[C@]3(C)[C@H]4CC[C@@H]5[C@H]6[C@H](C(C)C)CC[C@]6(C(=O)O)CC[C@@]5(C)[C@]4(C)CC[C@H]3C2(C)C)cc1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 11/20 0.53
PRKCD Q05655 1/20 0.53
NR1H4 Q96RI1 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16511856 0.93 NR1H4 (0.49) GPBAR1PRKCDNR1H4
SCHEMBL9891265 0.91 GPBAR1 (0.56) GPBAR1PRKCD
SCHEMBL9891336 0.90 GPBAR1 (0.57) GPBAR1PRKCD
SCHEMBL18525840 0.89
SCHEMBL15918674 0.89
SCHEMBL15947500 0.89
SCHEMBL9108376 0.89 NR1H4 (0.50) GPBAR1NR1H4
SCHEMBL15947454 0.89 NR1H4 (0.50) GPBAR1NR1H4
SCHEMBL15933732 0.88
SCHEMBL12698029 0.88 GPBAR1 (0.50) GPBAR1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920090-B2 Betulinic acid derivatives with HIV maturation inhibitory activity VIIV Healthcare UK (No.5) Limited (GB) 2018-03-20 US disclosed
US-20170204133-A1 BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2017-07-20 US disclosed
EP-2576586-B1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-8802661-B2 C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-12 US disclosed
US-20120142653-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 US disclosed
WO-2011153319-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142653-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS ERG28, BET1, BRD3 GPBAR1 2177/4885PRKCD 2347/4885NR1H4 2324/4885
US-20170204133-A1 BETULINIC ACID DERIVATIVES WITH HIV MATURATION INHIBITORY ACTIVITY BET1, PGGT1B, TMPO GPBAR1 1377/4885PRKCD 4019/4885NR1H4 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.